Imaxio SA has identified a molecule that it believes can boost the body’s recognition of many antigens, and stimulate the immune system to produce both B cells and T cells. Some people might consider the molecule a “genetic adjuvant,” but the company itself refers to it as a “carrier protein.” Whereas classic adjuvants that provoke the body to a stronger immune response are mixed in with vaccines, Imaxio’s carrier will be genetically fused to specific components of a vaccine. The distinction matters from a regulatory perspective, and should simplify the path to market. Because both B and T cells help protect the body from foreign invaders, mustering the two together could greatly improve the power of a vaccine.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.
GSK’s antibody-drug conjugate looks set for a blockbuster future in multiple myeloma after an approval in the UK, and the company’s head of oncology says it is already planning for the next generation of therapies.
